Hypogen, Inc., is a biopharmaceutical company focused on the development of novel diagnostic tests and new therapeutics for essential hypertension. Hypertension is the worldâs most prevalent disease, affecting more than 25 percent of the population, and continues to be a leading cause of morbidity and mortality. Hypogen Inc. is developing a new generation of drugs that, for the first time, would treat high blood pressure at the genetic level. Hypogen is also creating a simple diagnostic blood test that can determine if a person has specific genetic defects putting them at a significant risk of developing high blood pressure
